vs
AtriCure, Inc.（ATRC）与CARRIAGE SERVICES INC（CSV）财务数据对比。点击上方公司名可切换其他公司
AtriCure, Inc.的季度营收约是CARRIAGE SERVICES INC的1.3倍（$141.2M vs $105.5M），CARRIAGE SERVICES INC净利率更高（11.6% vs 0.1%，领先11.6%），AtriCure, Inc.同比增速更快（14.3% vs 8.0%），过去两年AtriCure, Inc.的营收复合增速更高（10.2% vs 1.0%）
AtriCure是一家专注于心房颤动及相关心脏病症治疗的医疗设备企业，研发并生产创新外科手术工具与疗法，主要服务北美、欧洲、亚太地区的医院、心脏外科中心及医疗机构，为微创心脏手术提供高效可靠的适配解决方案。
怡和Cycle & Carriage有限公司是怡和集团在东南亚的投资控股公司，目前该集团持有其75%的股份，是怡和集团在东南亚区域开展资本布局与投资业务的核心平台。
ATRC vs CSV — 直观对比
营收规模更大
ATRC
是对方的1.3倍
$105.5M
营收增速更快
ATRC
高出6.3%
8.0%
净利率更高
CSV
高出11.6%
0.1%
两年增速更快
ATRC
近两年复合增速
1.0%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $141.2M | $105.5M |
| 净利润 | $108.0K | $12.3M |
| 毛利率 | 77.4% | 34.8% |
| 营业利润率 | 23.0% | 23.3% |
| 净利率 | 0.1% | 11.6% |
| 营收同比 | 14.3% | 8.0% |
| 净利润同比 | — | 24.5% |
| 每股收益（稀释后） | $0.00 | $0.76 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ATRCCSV
| Q1 26 | $141.2M | — | ||
| Q4 25 | $140.5M | $105.5M | ||
| Q3 25 | $134.3M | $102.7M | ||
| Q2 25 | $136.1M | $102.1M | ||
| Q1 25 | $123.6M | $107.1M | ||
| Q4 24 | $124.3M | $97.7M | ||
| Q3 24 | $115.9M | $100.7M | ||
| Q2 24 | $116.3M | $102.3M |
净利润ATRCCSV
| Q1 26 | $108.0K | — | ||
| Q4 25 | — | $12.3M | ||
| Q3 25 | $-267.0K | $6.6M | ||
| Q2 25 | $-6.2M | $11.7M | ||
| Q1 25 | $-6.7M | $20.9M | ||
| Q4 24 | — | $9.9M | ||
| Q3 24 | $-7.9M | $9.9M | ||
| Q2 24 | $-8.0M | $6.3M |
毛利率ATRCCSV
| Q1 26 | 77.4% | — | ||
| Q4 25 | 75.0% | 34.8% | ||
| Q3 25 | 75.5% | 35.3% | ||
| Q2 25 | 74.5% | 35.2% | ||
| Q1 25 | 74.9% | 35.3% | ||
| Q4 24 | 74.5% | 34.4% | ||
| Q3 24 | 74.9% | 35.2% | ||
| Q2 24 | 74.7% | 36.2% |
营业利润率ATRCCSV
| Q1 26 | 23.0% | — | ||
| Q4 25 | 1.8% | 23.3% | ||
| Q3 25 | 0.2% | 17.0% | ||
| Q2 25 | -4.5% | 23.5% | ||
| Q1 25 | -4.8% | 29.5% | ||
| Q4 24 | -11.7% | 21.6% | ||
| Q3 24 | -6.4% | 22.7% | ||
| Q2 24 | -6.2% | 18.0% |
净利率ATRCCSV
| Q1 26 | 0.1% | — | ||
| Q4 25 | — | 11.6% | ||
| Q3 25 | -0.2% | 6.4% | ||
| Q2 25 | -4.5% | 11.5% | ||
| Q1 25 | -5.5% | 19.5% | ||
| Q4 24 | — | 10.1% | ||
| Q3 24 | -6.8% | 9.8% | ||
| Q2 24 | -6.9% | 6.1% |
每股收益（稀释后）ATRCCSV
| Q1 26 | $0.00 | — | ||
| Q4 25 | $0.04 | $0.76 | ||
| Q3 25 | $-0.01 | $0.41 | ||
| Q2 25 | $-0.13 | $0.74 | ||
| Q1 25 | $-0.14 | $1.34 | ||
| Q4 24 | $-0.33 | $0.62 | ||
| Q3 24 | $-0.17 | $0.63 | ||
| Q2 24 | $-0.17 | $0.40 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $146.2M | $1.7M |
| 总债务越低越好 | $61.0M | — |
| 股东权益账面价值 | $491.7M | $254.8M |
| 总资产 | $644.0M | $1.3B |
| 负债/权益比越低杠杆越低 | 0.12× | — |
8季度趋势，按日历期对齐
现金及短期投资ATRCCSV
| Q1 26 | $146.2M | — | ||
| Q4 25 | $167.4M | $1.7M | ||
| Q3 25 | $147.9M | $1.2M | ||
| Q2 25 | $117.8M | $1.4M | ||
| Q1 25 | $99.9M | $4.6M | ||
| Q4 24 | $122.7M | $1.2M | ||
| Q3 24 | $130.3M | $1.3M | ||
| Q2 24 | $114.0M | $1.5M |
总债务ATRCCSV
| Q1 26 | $61.0M | — | ||
| Q4 25 | — | — | ||
| Q3 25 | $61.9M | — | ||
| Q2 25 | $61.9M | — | ||
| Q1 25 | $61.9M | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $61.9M | — | ||
| Q2 24 | $61.9M | — |
股东权益ATRCCSV
| Q1 26 | $491.7M | — | ||
| Q4 25 | $491.9M | $254.8M | ||
| Q3 25 | $476.5M | $242.1M | ||
| Q2 25 | $464.5M | $235.4M | ||
| Q1 25 | $454.6M | $223.1M | ||
| Q4 24 | $461.0M | $208.6M | ||
| Q3 24 | $465.0M | $198.1M | ||
| Q2 24 | $462.1M | $187.9M |
总资产ATRCCSV
| Q1 26 | $644.0M | — | ||
| Q4 25 | $654.2M | $1.3B | ||
| Q3 25 | $635.4M | $1.3B | ||
| Q2 25 | $608.8M | $1.3B | ||
| Q1 25 | $591.6M | $1.3B | ||
| Q4 24 | $609.3M | $1.3B | ||
| Q3 24 | $615.1M | $1.3B | ||
| Q2 24 | $597.3M | $1.3B |
负债/权益比ATRCCSV
| Q1 26 | 0.12× | — | ||
| Q4 25 | — | — | ||
| Q3 25 | 0.13× | — | ||
| Q2 25 | 0.13× | — | ||
| Q1 25 | 0.14× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 0.13× | — | ||
| Q2 24 | 0.13× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $14.1M |
| 自由现金流经营现金流 - 资本支出 | — | $6.2M |
| 自由现金流率自由现金流/营收 | — | 5.9% |
| 资本支出强度资本支出/营收 | — | 7.5% |
| 现金转化率经营现金流/净利润 | — | 1.15× |
| 过去12个月自由现金流最近4个季度 | — | $40.1M |
8季度趋势，按日历期对齐
经营现金流ATRCCSV
| Q1 26 | — | — | ||
| Q4 25 | $20.0M | $14.1M | ||
| Q3 25 | $26.7M | $24.7M | ||
| Q2 25 | $21.6M | $8.1M | ||
| Q1 25 | $-11.0M | $13.8M | ||
| Q4 24 | $5.8M | $9.3M | ||
| Q3 24 | $20.0M | $20.9M | ||
| Q2 24 | $7.4M | $2.2M |
自由现金流ATRCCSV
| Q1 26 | — | — | ||
| Q4 25 | $18.4M | $6.2M | ||
| Q3 25 | $24.1M | $18.0M | ||
| Q2 25 | $19.0M | $5.2M | ||
| Q1 25 | $-13.2M | $10.6M | ||
| Q4 24 | $3.1M | $4.9M | ||
| Q3 24 | $16.4M | $16.2M | ||
| Q2 24 | $5.0M | $-1.4M |
自由现金流率ATRCCSV
| Q1 26 | — | — | ||
| Q4 25 | 13.1% | 5.9% | ||
| Q3 25 | 18.0% | 17.5% | ||
| Q2 25 | 13.9% | 5.1% | ||
| Q1 25 | -10.7% | 9.9% | ||
| Q4 24 | 2.5% | 5.0% | ||
| Q3 24 | 14.1% | 16.1% | ||
| Q2 24 | 4.3% | -1.4% |
资本支出强度ATRCCSV
| Q1 26 | — | — | ||
| Q4 25 | 1.1% | 7.5% | ||
| Q3 25 | 1.9% | 6.5% | ||
| Q2 25 | 2.0% | 2.8% | ||
| Q1 25 | 1.8% | 3.0% | ||
| Q4 24 | 2.2% | 4.5% | ||
| Q3 24 | 3.1% | 4.6% | ||
| Q2 24 | 2.1% | 3.5% |
现金转化率ATRCCSV
| Q1 26 | — | — | ||
| Q4 25 | — | 1.15× | ||
| Q3 25 | — | 3.76× | ||
| Q2 25 | — | 0.69× | ||
| Q1 25 | — | 0.66× | ||
| Q4 24 | — | 0.94× | ||
| Q3 24 | — | 2.11× | ||
| Q2 24 | — | 0.34× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ATRC
| Appendage management | $48.4M | 34% |
| Open ablation | $39.1M | 28% |
| Other | $25.0M | 18% |
| Pain management | $22.4M | 16% |
| Minimally invasive ablation | $6.4M | 5% |
CSV
| Propertyand Merchandise | $47.8M | 45% |
| Cemetery Interment Rights | $24.8M | 23% |
| Merchandise | $18.9M | 18% |
| Other Revenue | $10.2M | 10% |
| Other | $3.9M | 4% |
